Literature DB >> 24447817

Characterization of a monoclonal antibody capable of reliably quantifying expression of human Copper Transporter 1 (hCTR1).

Jacob F Quail1, Cheng-Yu Tsai1, Stephen B Howell2.   

Abstract

Human copper transporter 1 (hCTR1) is the high-affinity copper influx transporter in mammalian cells that also mediates the influx of cisplatin. Loss of hCTR1 expression has been implicated in the development of resistance to this cancer chemotherapeutic agent. It has turned out to be very difficult to develop antibodies to hCTR1 and polyclonal antibodies produced by different laboratories have yielded conflicting results. We have characterized a newly-available rabbit monoclonal antibody that reacts with an epitope on the N-terminal end of hCTR1 that now permits rigorous identification and quantification of hCTR1 using Western blot analysis. Postnuclear membrane (PNM) preparations made from cells engineered to express high levels of myc-tagged hCTR1, and cells in which the expression of hCTR1 was knocked down, were used to characterize the antibody. The identity of the bands detected was confirmed by immunoprecipitation, surface biotinylation and deglycosylation of myc-tagged hCTR1. Despite the specificity expected of a monoclonal antibody, the anti-hCTR1 detected a variety of bands in whole cell lysates (WCL), which made it difficult to quantify hCTR1. This problem was overcome by isolating post-nuclear membranes and using these for further analysis. Three bands were identified using this antibody in PNM preparations that migrated at 28, 33-35 and 62-64kDa. Multiple lines of evidence presented here suggest that the 33-35 and 62-64kDa bands are hCTR1 whereas the 28kDa band is a cross-reacting protein of unknown identify. The 33-35kDa band is consistent with the expected MW of the glycosylated hCTR1 monomer. This analysis now permits rigorous identification and quantification of hCTR1.
Copyright © 2013 Elsevier GmbH. All rights reserved.

Entities:  

Keywords:  Copper; Copper transporter 1; Monoclonal antibody; Transporter; Western blot

Mesh:

Substances:

Year:  2013        PMID: 24447817      PMCID: PMC3989404          DOI: 10.1016/j.jtemb.2013.12.003

Source DB:  PubMed          Journal:  J Trace Elem Med Biol        ISSN: 0946-672X            Impact factor:   3.849


  41 in total

1.  Prognostic value of the copper transporters, CTR1 and CTR2, in patients with ovarian carcinoma receiving platinum-based chemotherapy.

Authors:  Yoo-Young Lee; Chel Hun Choi; In-Gu Do; Sang Yong Song; Wooseok Lee; Hwang Shin Park; Tae Jong Song; Min Kyu Kim; Tae-Joong Kim; Jeong-Won Lee; Duk-Soo Bae; Byoung-Gie Kim
Journal:  Gynecol Oncol       Date:  2011-05-13       Impact factor: 5.482

2.  Enhancing tumor-specific uptake of the anticancer drug cisplatin with a copper chelator.

Authors:  Seiko Ishida; Frank McCormick; Karen Smith-McCune; Douglas Hanahan
Journal:  Cancer Cell       Date:  2010-06-15       Impact factor: 31.743

3.  A re-evaluation of the role of hCTR1, the human high-affinity copper transporter, in platinum-drug entry into human cells.

Authors:  Kristin D Ivy; Jack H Kaplan
Journal:  Mol Pharmacol       Date:  2013-03-29       Impact factor: 4.436

4.  Organic cation transporter 2 mediates cisplatin-induced oto- and nephrotoxicity and is a target for protective interventions.

Authors:  Giuliano Ciarimboli; Dirk Deuster; Arne Knief; Michael Sperling; Michael Holtkamp; Bayram Edemir; Hermann Pavenstädt; Claudia Lanvers-Kaminsky; Antoinette am Zehnhoff-Dinnesen; Alfred H Schinkel; Hermann Koepsell; Heribert Jürgens; Eberhard Schlatter
Journal:  Am J Pathol       Date:  2010-01-28       Impact factor: 4.307

5.  Sec61β controls sensitivity to platinum-containing chemotherapeutic agents through modulation of the copper-transporting ATPase ATP7A.

Authors:  Paolo B Abada; Christopher A Larson; Gerald Manorek; Preston Adams; Stephen B Howell
Journal:  Mol Pharmacol       Date:  2012-06-18       Impact factor: 4.436

6.  Predictive and prognostic value of human copper transporter 1 (hCtr1) in patients with stage III non-small-cell lung cancer receiving first-line platinum-based doublet chemotherapy.

Authors:  Helen H W Chen; Jiang-Jou Yan; Wen-Chung Chen; Macus Tien Kuo; Yu-Hsuan Lai; Wu-Wei Lai; Hsiao-Sheng Liu; Wu-Chou Su
Journal:  Lung Cancer       Date:  2011-07-23       Impact factor: 5.705

7.  Overcoming platinum resistance through the use of a copper-lowering agent.

Authors:  Siqing Fu; Aung Naing; Caroline Fu; Macus Tien Kuo; Razelle Kurzrock
Journal:  Mol Cancer Ther       Date:  2012-04-05       Impact factor: 6.261

8.  Copper influx transporter 1 is required for FGF, PDGF and EGF-induced MAPK signaling.

Authors:  Cheng-Yu Tsai; J Cameron Finley; Sameh S Ali; Hemal H Patel; Stephen B Howell
Journal:  Biochem Pharmacol       Date:  2012-07-25       Impact factor: 5.858

9.  Three-dimensional structure of the human copper transporter hCTR1.

Authors:  Christopher J De Feo; Stephen G Aller; Gnana S Siluvai; Ninian J Blackburn; Vinzenz M Unger
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-24       Impact factor: 11.205

10.  Regulation of Cisplatin cytotoxicity by cu influx transporters.

Authors:  Paolo Abada; Stephen B Howell
Journal:  Met Based Drugs       Date:  2011-01-09
View more
  4 in total

1.  The copper transporter 1 (CTR1) is required to maintain the stability of copper transporter 2 (CTR2).

Authors:  Cheng-Yu Tsai; Janika K Liebig; Igor F Tsigelny; Stephen B Howell
Journal:  Metallomics       Date:  2015-07-24       Impact factor: 4.526

2.  Molecular modulation of the copper and cisplatin transport function of CTR1 and its interaction with IRS-4.

Authors:  Cheng-Yu Tsai; Christopher A Larson; Roohangiz Safaei; Stephen B Howell
Journal:  Biochem Pharmacol       Date:  2014-06-23       Impact factor: 5.858

3.  Dextran-Catechin inhibits angiogenesis by disrupting copper homeostasis in endothelial cells.

Authors:  Eugene M H Yee; Miriam B Brandl; Eddy Pasquier; Giuseppe Cirillo; Kathleen Kimpton; Maria Kavallaris; Naresh Kumar; Orazio Vittorio
Journal:  Sci Rep       Date:  2017-08-09       Impact factor: 4.379

4.  Dextran-Catechin: An anticancer chemically-modified natural compound targeting copper that attenuates neuroblastoma growth.

Authors:  Orazio Vittorio; Miriam Brandl; Giuseppe Cirillo; Kathleen Kimpton; Elizabeth Hinde; Katharina Gaus; Eugene Yee; Naresh Kumar; Hien Duong; Claudia Fleming; Michelle Haber; Murray Norris; Cyrille Boyer; Maria Kavallaris
Journal:  Oncotarget       Date:  2016-07-26
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.